HC Wainwright Has Positive Outlook of WVE FY2028 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Stock analysts at HC Wainwright lifted their FY2028 EPS estimates for shares of Wave Life Sciences in a report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will post earnings of $1.27 per share for the year, up from their prior estimate of $1.23. HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.09) per share.

Other equities research analysts have also issued research reports about the stock. JPMorgan Chase & Co. upped their price target on shares of Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, October 17th. Leerink Partners boosted their price objective on shares of Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday. Raymond James upgraded shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $13.00 to $22.00 in a research note on Wednesday, October 16th. Finally, Royal Bank of Canada boosted their price target on Wave Life Sciences from $7.00 to $15.00 and gave the stock a “sector perform” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $21.89.

Wave Life Sciences Trading Down 8.9 %

Shares of NASDAQ:WVE opened at $13.67 on Friday. The stock has a fifty day simple moving average of $10.76 and a two-hundred day simple moving average of $7.52. Wave Life Sciences has a 12-month low of $3.50 and a 12-month high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.19). The business had revenue of ($7.68) million for the quarter, compared to the consensus estimate of $15.45 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%.

Institutional Investors Weigh In On Wave Life Sciences

Large investors have recently added to or reduced their stakes in the stock. Swiss National Bank raised its holdings in Wave Life Sciences by 2.7% during the 1st quarter. Swiss National Bank now owns 156,500 shares of the company’s stock worth $966,000 after buying an additional 4,100 shares during the period. ProShare Advisors LLC grew its position in shares of Wave Life Sciences by 35.0% in the first quarter. ProShare Advisors LLC now owns 21,764 shares of the company’s stock valued at $134,000 after purchasing an additional 5,648 shares during the last quarter. Vanguard Group Inc. increased its position in Wave Life Sciences by 39.7% in the 1st quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock worth $11,316,000 after buying an additional 521,665 shares during the period. Ameritas Investment Partners Inc. increased its position in Wave Life Sciences by 50.2% during the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock worth $45,000 after acquiring an additional 2,451 shares during the period. Finally, American International Group Inc. lifted its stake in shares of Wave Life Sciences by 23.3% in the first quarter. American International Group Inc. now owns 36,241 shares of the company’s stock valued at $224,000 after buying an additional 6,851 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Wave Life Sciences

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Kyle Moran sold 17,146 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the completion of the transaction, the chief financial officer now directly owns 19,777 shares in the company, valued at approximately $177,993. The trade was a 46.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 452,056 shares of company stock valued at $5,955,438. 29.10% of the stock is owned by corporate insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.